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Abstract
Tumor cells escape the immune surveillance system of the host through a process called immune tolerance.
Immunotherapy targets molecules that serve as checks and balances in the regulation of immune response.
Indoleamine-2,3-dioxygenase (IDO) is an intracellular enzyme, which through the process of tryptophan depletion
exerts an immunosuppressive effect, facilitating immune escape of tumors. This review summarizes our current
knowledge on IDO expression in malignancies, the IDO inhibitors that are currently available and those under
clinical development.
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Introduction
Most tumors express potentially immunogenic antigens
to which the immune system can respond [1]. In turn,
the tumor-bearing host possesses high-avidity T cells
that are specific to these antigens [2]. And yet, in a
phenomenon called immune tolerance, tumor cells
evolve to escape immune surveillance [3], and the host
fails to reject the tumor. A number of molecular mech-
anisms underlying this induced tolerance have been
identified [4]. Immunotherapies targeting such mecha-
nisms have become an important therapeutic strategy
for harnessing the immune system’s ability to control
malignancy, overcoming immune tolerance.
Indoleamine-2,3-dioxygenase (IDO) is an intracellular
heme-containing enzyme that initiates the first and rate-
limiting step of tryptophan degradation along the kynur-
enine pathway [5]. In mammalian organisms, tryptophan
is an essential amino acid for cell survival; it cannot be
synthesized de novo. Initially, the role of IDO was
thought to be mainly antimicrobial by reducing the
availability of tryptophan in the inflammatory environ-
ment [6–8]. IDO was shown to be expressed in normal
tissues such as the endothelial cells in the placenta and
lung, the epithelial cells in the female genital tract, and
the lymphoid tissues in mature dendritic cells (DCs) [9].
An innovative discovery by Munn and colleagues
showed that IDO has a central role in preventing T
cell-driven rejection of allogeneic fetuses during preg-
nancy as trophoblast expressing IDO was found to in-
duce maternal tolerance to fetal allograft [10]. This
discovery broke ground for further research address-
ing the immunomodulatory potential of IDO, includ-
ing a series of studies focused on the role of IDO in
the immune escape of tumors, reviewed earlier by
Zou [4]. The immunosuppressive roles of IDO have
also been investigated for elucidation of therapeutic
targets in the management of autoimmune diseases
[11] and for induction of graft tolerance after trans-
plantation [12–15].
Several reviews discussing the enzymatic activity of
IDO have been published [16–22]. The aims of this art-
icle are however, to summarize the most recent data on
IDO expression in malignancies and to discuss the
current status of clinical testing of IDO inhibitors.
Review
Mechanisms of IDO pathway involvement in immune
tolerance
IDO is an important enzyme in both cancer develop-
ment and cancer progression. IDO supports inflam-
mation in the tumor microenvironment, development
of immune tolerance to tumor antigens in stromal
and immune cells, suppression of T and natural killer
cells, generation and activation of T regulatory cells
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(Tregs) and myeloid-derived suppressor cells, and
promotion of tumor angiogenesis [23].
Growing tumors evade the immune system of the
host through a complex process of immunoediting in
the tumor, where selective pressures result in the out-
growth of tumor clones capable of evading and suppress-
ing active immunity, which often includes expression of
tolerance mechanisms. The IDO pathway is one of the en-
dogenous pathways used often by tumor cells to induce
tolerance to tumor antigens [21].
As noted above, IDO is expressed by endothelial cells
[24], mesenchymal stromal cells, fibroblasts [25], and
various myeloid-derived antigen-presenting cells such as
DCs and macrophages [26], as well as by tumor cells
[23, 27]. However, some discrepancies in IDO expression
profiles in normal and tumor tissues as well as cell types
expressing IDO exist. For example, high expression of
IDO in tumor draining lymph nodes (TDLN) was asso-
ciated with poor clinical outcomes [28, 29]. However, re-
cently it has been reported that TDLNs do not contain
more IDO+ cells than normal lymph nodes in a study
conducted in 15 patients with breast cancer and 15 pa-
tients with melanoma [9]. Similarly, multi-fold increase
in expression of IDO was reported with mature DCs but
not in immature DCs [9, 30]. On the contrary, some
studies have reported expression of IDO1 by immature
DCs or plasmacytoid DCs [28, 29]. Despite these dis-
crepancies, the expression of IDO by antigen-presenting
cells can lead directly to suppression of tumor-specific
T-cell responses [27] and to activation of Tregs [31].
These effects can be achieved via multiple mechanisms,
as demonstrated in Fig. 1.
An important mechanism by which IDO affects T-cell
activity is that the consumption of local tryptophan in-
hibits mechanistic target of rapamycin (serine/threonine
kinase) complex 1 (mTORC1) [32] as well as the T-cell
receptor regulatory kinase, protein kinase C theta (PKC-
θ) [32], both of which are regulatory targets of the mas-
ter amino acid-sensing kinase, glucokinase (GLK1) [33].
mTORC1 inhibition can trigger a response that includes
activating autophagy, leading to anergy in T cells in the
tumor microenvironment [21].
IDO expression can further induce a stress response in
cells via activation of general control nondepressible-2
(GCN2). Tryptophan degradation by IDO causes local
tryptophan deficiency, leading to the accumulation of
uncharged tryptophan transfer ribonucleic acid (tRNA)
in cells. GCN2, a stress-response kinase, is stimulated by
elevations in uncharged tRNA, and its activation can
limit or alter protein translation [34] and prevent T-cell
activation [35, 36]. Furthermore, activation of GCN2
promotes de novo Treg differentiation and enhances
Treg activity, resulting in profound immunosuppressive
microenvironment [36, 37].
An additional mechanism by which IDO expression al-
ters the tumor microenvironment and favors immune
Fig. 1 Mechanisms of IDO pathway activity in immune tolerance. The enzyme IDO catalyzes the initial and rate-limiting step in the catabolism of
tryptophan along the kynurenine pathway. Accordingly, IDO can provoke tryptophan shortage, which results in mTORC1 inhibition and GCN2
activation, in turn leading to anergy of effector T cells. Tryptophan’s degradation leads to production of bioactive kynurenine pathway compounds,
which activate the AHR, resulting in promotion of Treg differentiation. TC, tumor cell; DC, dendritic cell; MФ, macrophage; EC, endothelial
cell; FB, fibroblast; IDO, indoleamine-2,3-dioxygenase 1; Trp, tryptophan; Krn, kynurenine; mTORC1, mechanistic target of rapamycin (serine/
threonine kinase) complex 1; GCN2, general control nondepressible-2; AHR, aryl hydrocarbon receptor; Treg, regulatory T cell
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tolerance is through the production of bioactive com-
pounds. One such compound, kynurenine, which is
produced by enzymatic activity of IDO on tryptophan,
activates transcription of the aryl hydrocarbon recep-
tor (AHR). Through the AHR, kynurenine metabolites
promote differentiation of forkhead box P3-positive
(FOXP3+) Tregs [38] and suppression of antitumor
immune responses [39]. All three effects of AHR pathway
signaling lead to anergy of effector T cells and activation
of Tregs.
Sharma, Munn and colleagues showed that in mel-
anoma mouse models, IDO is expressed by DCs in
the tumor-draining lymph nodes (where tumors are
exposed to the antigen-presenting cells for the first
time), leading to potent suppression of cluster of dif-
ferentiation (CD)8+ T-cell responses and to systemic
tumor tolerance [40–42]. Those DCs, when harvested
from the tumor-draining nodes and adoptively trans-
ferred into new hosts, led to suppression of T-cell re-
sponses in vitro, as well as antigen-specific T-cell
anergy in vivo [29, 43]. In mouse models, IDO-
expressing DCs activated Tregs, which then systemic-
ally suppressed antitumor T-cell responses [37]. The
increases in Treg activity are achieved by activation
of existing natural Tregs and by upregulation of
FOXP3 expression in CD4b+ T cells so that they dif-
ferentiate into new inducible Tregs [37, 42, 44]. Simi-
lar studies showed that IDO-expressing plasmacytoid
DCs [45, 46] and IDO-expressing monocyte-derived
(myeloid) DCs [22] induced differentiation of CD4+
cells into FOXP3+ Treg-like cells.
Role of the IDO pathway in cancers
Aberrant IDO activity has been associated with a
wide variety of non-oncologic human pathological
conditions, including autoimmune diseases, infectious
diseases, depression, obesity, organ and bone marrow
transplantation and atherosclerosis. Direct evidence of
IDO’s role has been obtained by studying patients, as
well as relevant animal models [47–52].
Several lines of in vitro [53, 54] and in vivo [27, 29]
evidence suggest that the IDO pathway plays a key
role in regulating immune evasion by tumors. Recent
evidence has demonstrated that the functionally active
IDO protein is expressed in a wide variety of human
hematologic malignancies, such as acute monocytic
leukemia, [55] acute lymphocytic leukemia, [55] acute
myeloid leukemia [56] and T-cell leukemia/lymphoma
[27], and solid tumors, such as breast cancer [27, 57],
colorectal cancer [27], endometrial cancer [27], gastric
cancer [27], glioblastoma [27], gynecological cancers
[58], head and neck cancers [27], non-small cell lung
cancer (NSCLC) [27], small cell lung cancer [27], melan-
oma [27], mesothelioma [27], and pancreatic cancer [27].
In contrast, most normal cells of the stroma were
found to be negative for IDO expression [27]. Several
studies have attempted to link IDO activity with its
proposed mechanism of action, demonstrating that
IDO expression/activity is associated with reduced
intratumoral T-cell infiltration, disease progression,
and decreased shorter overall survival. For example,
an increased kynurenine/tryptophan ratio in the blood
was associated with a shorter survival time in patients
with acute myeloid leukemia [59]. In patients with
solid tumors, such as colorectal cancer [60, 61], endo-
metrial cancer [62, 63], small cell lung cancer [64],
melanoma [65], and ovarian cancer [66, 67], high
IDO expression is correlated with a poor prognosis
and shorter overall survival. The shorter survival of
patients whose tumors overexpress IDO supports the
concept that a treatment strategy of IDO blockade
will have antitumor effects. IDO is thus an attractive
target for therapeutic intervention.
IDO may also be involved in mechanisms leading to
chemoresistance in cancer patients. In a study of gene
expression profiling associated with paclitaxel resist-
ance in patients with serous ovarian cancer, IDO was
the most prominently expressed gene. This finding was
confirmed with real-time reverse transcription-polymerase
chain reaction and immunohistochemistry [67].
Furthermore, the regulation of IDO was demonstrated
to contribute substantially to the antitumor effects of
imatinib in a mouse model of spontaneous gastrointes-
tinal stromal tumor [68]. Imatinib activated CD8+ T cells
and induced Treg apoptosis within the tumor by redu-
cing tumor cell expression of IDO [68]. It is speculated
that concomitant immunotherapy with an IDO inhibitor
may further improve outcomes in gastrointestinal stro-
mal tumor treated with imatinib.
IDO inhibition as a therapeutic strategy
There has been increasing scientific interest in IDO as a
novel therapeutic target for the development of new
cancer drugs, based on the in vitro and in vivo evidence
for immune tolerance in the setting of IDO expression
in tumor cells and the clinical evidence for poor progno-
sis and chemoresistance in tumors with high IDO ex-
pression. Indeed, potential IDO-inhibiting drugs for use
in human cancers are now the focus of research and de-
velopment efforts. Current inhibitors of IDO are listed
in Table 1.
Among the IDO inhibitors, 1-methyl-DL-tryptophan
(1-MT) has been the most widely studied. There are 2
available stereoisomers of 1-MT, D and L isomers, with
potentially different biochemical and antitumor activity
[69]. Pioneering work performed by Hou et al revealed
cell-type specific variations in the activity of the 1-MT
isomers. In in-vitro studies, the L isomer (L-1MT) is
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superior in inhibiting the enzymatic activity of IDO
(kynurenine production from tryptophan) in cell-free
assays, and several cell lines [69]. Nevertheless, D iso-
mer (D-1MT) is equally effective in inhibiting the en-
zymatic activity of IDO in human monocyte-derived
DCs in allogeneic mixed lymphocyte reactions (MLRs)
and is significantly superior to L-1MT or DL mixture
in inducing T-cell proliferation in allo-MLRs using
either human T cells stimulated by IDO-expressing
monocyte-derived DCs or murine T cells stimulated
by IDO-expressing plasmacytoid DCs from tumor-
draining lymph nodes [69]. However, this effect is not
observed in MLRs using IDO-KO DCs, indicating
that the D-1MT exerted its effect in allo-MLRs dir-
ectly by its action on the IDO gene [69]. Hou et al
attributed the cell-type specific variations in the activ-
ity of the 1-MT isomers to the possible existence of
IDO isoforms. In addition, a statistically significant
prolongation of survival is observed with D-1MT in com-
bination with cyclophosphamide in orthotopic 4 T1-luc
tumors and in combination with paclitaxel in the autoch-
thonous MMTV-Neu breast tumor model, compared to
L-1MT [69]. The superiority of one isomer over the other
is therefore dependent on the biological context of IDO
expression, tumor cells versus host dendritic cells.
Based on the above findings, D-1MT has been consid-
ered more suitable for further clinical development.
Soon after, Metz et al reported the discovery of a novel
IDO-related tryptophan-catabolizing enzyme, IDO2
that is coded by a gene, IDO2, upstream of the INDO
gene that codes for IDO (dubbed IDO1). Though IDO2
shares structural similarity to IDO1 [70], IDO2 is
expressed only in a subset of tissues that express IDO1
but includes DCs [71]. Consistent with the observations
made by Hou et al, Metz et al demonstrated that L-
1MT modestly inhibits IDO1 activity, whereas D-1MT
inhibits IDO2. This possibly explains the greater anti-
tumor activity of D-1MT in preclinical models. Des-
pite the superior antitumor activity of D-1MT, the
response to treatment may be negated by the exist-
ence of functionally inactive polymorphisms in the
IDO2 gene that ablate the enzymatic activity in ap-
proximately 50 % of white populations and 25 % of
individuals of African descent [71]. The genetic status
of the patient regarding IDO2 gene may serve as a
predictive marker of response.
Contrary to these findings, Lob et al reported that
D-1MT may not be an effective therapeutic option
based on a study in a subset of human DCs [72]. Fol-
lowing treatment of interferon-γ-treated mature DCs
with IDO1-specific siRNA, IDO1 transcription was si-
lenced; while expression of IDO2 was unaffected. In
addition, tryptophan and kynurenine concentrations
were restored following treatment with IDO1-specific
siRNA. Similar results were observed in tumor sam-
ples that were known to constitutively express IDO
[73]. Based on these findings, Lob et al concluded that the
IDO activity is only due to IDO1; and IDO2 though
expressed by human DCs, was functionally inactive. There-
fore inhibition of IDO activity in human DCs by D-1MT
was considered unlikely, despite its activity in mice [73,
74]. More recently, genetic ablation of IDO1 alone was suf-
ficient to phenocopy IDO‐inhibition with either D‐1MT or
combined D- and L-1MT regarding important biomarkers
of immune activation after chemo‐radiation therapy in a
mouse brain tumor model [75]. Based on this finding
therapeutic inhibition of IDO pathway largely directed
against IDO1 has been explored [76]. Despite the inability
or poor ability to inhibit the enzymatic activity of IDO, D-
1MT exhibits superior antitumor activity. It is speculated
that it interferes with IDO function at other levels besides
its inhibitory action on IDO2 [32]. An incidental finding
Table 1 Reported IDO inhibitors
Agent Mechanism First author, year
D-1MT Tryptophan mimetic; D isoform of MT; Transcriptional suppressor of IDO Metz 2012 [32]
L-1MT Tryptophan mimetic; L isoform of MT; selective IDO1 inhibitor Opitz 201 [39]
MTH-Trp Tryptophan mimetic; transcriptional suppressor of IDO Okamoto 2007 [92]
β-carbolines Tryptophan mimetic; IDO and TDO inhibitor Eguchi 1984 [93]
Naphthoquinone-based Pharmacophore of natural product annulin B; indole mimetic; IDO inhibitor Kumar 2008 [94]
S-allyl-brassinin Phytoalexin; indole mimetic Gaspari 2006 [95]
S-benzyl-brassinin Phytoalexin; indole mimetic Gaspari 2006 [95]
5-Bromo-brassinin Phytoalexin; indole mimetic Banerjee 2008 [96]
Phenylimidazole-based Computationally designed synthetic IDO inhibitor Kumar 2008 [94]
4-phenylimidazole Heme ligand in IDO enzyme Sono 1989 [97]
Exiguamine A Non-tryptophan analogue Harry 2006 [98]
NSC401366 Non-indolic IDO inhibitor Vottero 2006 [99]
IDO Indoleamine-2,3-dioxygenase 1, 1MT 1-methyl-DL-tryptophan, MTH-Trp methylthiohydantoin-dl-tryptophan, TDO tryptophan-2,3-dioxygenase
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that D-1MT acts as a potent tryptophan mimetic in
mTOR regulation by restoration of mTOR pathway is
one such possible mechanism of action [32]. Further,
IDO-mediated catabolism of tryptophan also inhibits
the immunoregulatory kinases mTOR and PKC-θ, in
addition to inducing autophagy. These effects were
also relieved specifically by tryptophan and D-1MT
[32]. On the contrary, the immunostimulatory effect
of L-1MT is limited by activation of the AHR path-
way in response to production of N-methyl-kynurenine, a
metabolite of L-1MT. These factors help to explain why
L-1MT is considered a poor physiological inhibitor of
IDO in comparison to D-1MT and why D-1MT has
broader clinical uses against cancers that overexpress any
tryptophan catabolic enzyme, such as IDO1, IDO2 and
tryptophan-2,3-dioxygenase (TDO) [32].
IDO inhibitors under clinical development
Currently, four IDO inhibitors are under clinical develop-
ment (Table 2): INCB024360 (developer: Incyte) [76, 77],
indoximod (D-1MT; developer: NewLink Genetics)
[32], an IDO peptide vaccine (developer: Copenhagen
University) [78], and NLG919 (developer: NewLink
Genetics, recently licensed to Genentech) [79].
INCB024360 is an orally administered hydroxyamidine
small molecule inhibitor of IDO1. The findings of a
phase I study of this IDO inhibitor were reported during
a poster discussion session at the 2013 American
Society of Clinical Oncology (ASCO) annual meeting
[80]. This study was an open-label, single-agent dose-
escalation trial in 52 patients with advanced malignancies
(NCT01195311). Using two independent pharmacody-
namic assays, IDO1 inhibition was observed in all
patients receiving the compound. Treatment with ≥
300 mg INCB024360 twice a day resulted in greater
than 90 % inhibition of IDO1 activity, and the drug was
well tolerated. The most common grade 1 or 2 adverse
events were fatigue and gastrointestinal disturbances,
and the most common grade 3 or 4 adverse events were
abdominal pain, hypokalemia and fatigue. The max-
imum tolerated dose was not established, but based on
the pharmacokinetic and pharmacodynamic data indi-
cating that prespecified target inhibition was achieved
and on the available tablet strengths, the recommended
dose for a phase II study was 600 mg twice daily. The
compound led to stable disease for greater than 8 weeks
in approximately 30 % of these patients with highly re-
fractory disease; half of the patients had colorectal
cancer, which has been refractory to most immunother-
apy approaches. Together, these results suggest that
INCB024360 has the potential to be effective as mono-
therapy, but, since it was so well tolerated, it may be
particularly useful in combination with other cancer
agents. Currently, two phase II trials of INCB024360
Table 2 Clinical trials using IDO inhibitors
Drug Phase Mono or combo Cancer Clinical trial ID Comments
INCB 024360 I Mono All NCT01195311 ASCO 2013
Ib/II With ipilimumab Melanoma NCT01604889 ASCO 2014/Recruiting
II With MELITAC 12.1 Melanoma NCT01961115 Recruiting
II Mono Ovary NCT01685255 Recruiting
II Mono MDS NCT01822691 Recruiting
Ib/II With MK3475 All/NSCLC NCT02178722 Recruiting
Ib/II With CDX-1401, poly ICLC Ovary NCT02166905 Recruiting
Pilot Mono Ovary (neoaduvant) NCT02042430 Recruiting
Indoximod (NLG2101) I Mono All NCT00739609 ASCO 2012
Ib With docetaxel All NCT01191216 ASCO 2013
Ib/II With AD.p53 DC vaccine All/breast NCT01042535 ASCO 2013/Recruiting
II With docetaxel Breast (HER2-) NCT01792050 Recruiting
II Mono Prostate NCT01560923 Recruiting
II With sipuleucel-T Prostate NCT01560923 Recruiting
Ib/II With nab-paclitaxel, gemcitabine Pancreas NCT02077881 Recruiting
Ib/II With ipilimumab Melanoma NCT02073123 Recruiting
Ib/II With temozolomide Brain NCT02052648 Recruiting
IDO peptide vaccine I With imiquimod, montanide NSCLC NCT01219348 Iversen 2013 [78]
Ib With temozolomide Melanoma NCT01543464 Recruiting
NLG919 I Mono All NCT02048709 Recruiting
DC dendritic cell, MDS myelodysplastic syndrome, NSCLC non-small cell lung cancer
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monotherapy are recruiting patients with ovarian cancer
(NCT01685255) or myelodysplastic syndrome (NCT018
22691). Furthermore, INCB024360 monotherapy is being
tested in a neoadjuvant pilot study in ovarian cancer
(NCT02042430).
Combining INCB024360 and other immunotherapy
modalities such as a cancer vaccine or immune check-
point inhibitor is being actively investigated based on
preclinical data showing synergism of IDO inhibitors
and other immune checkpoint blockade strategies [81,
82]. In a phase Ib study of INCB024360 in combination
with ipilimumab in patients with advanced melanoma
(NCT01604889), which was presented at the 2014
ASCO annual meeting [83], tumor response and dur-
ation data suggested the potential for enhanced outcomes
with combination treatment compared to ipilimumab
monotherapy in melanoma patients. Furthermore, a phase
Ib/II study of INCB024360 in combination with another
immune checkpoint inhibitor, MK3475, which is a pro-
grammed cell death-1 (PD-1) inhibitor, has just started
(NCT02178722). Two clinical trials of INCB024360 com-
bined with cancer vaccines are recruiting patients: a phase
II pilot study in combination with MELITAC 12.1, which
is a multipeptide melanoma vaccine (NCT01961115); and
a phase Ib/II study in combination with both CDX-140
[84], which is a vaccine for tumor antigen NY-ESO-1, and
poly ICLC [84], which is a viral mimic composed of
stabilized double-stranded RNA that acts as a ligand
to Toll-like receptor 3 (NCT02166905).
Indoximod (NLG2101), which is D-1MT, is an orally
administered IDO pathway inhibitor. An initial phase I
study of indoximod as a single agent demonstrated good
oral bioavailability and a favorable safety profile [85].
Based on these findings, a phase Ib trial of indoximod in
combination with docetaxel (NCT01191216) was con-
ducted in 27 patients; the results were reported at the
ASCO annual meeting in 2013 [86]. The data showed
that among 22 evaluable patients, 18 % (4/22; 2 with
breast cancer; 1, NSCLC; 1, thymus cancer) exhibited a
partial response, and 41 % (9/22; 4 with breast cancer; 2,
NSCLC; 1, laryngeal cancer; 1, esophageal cancer; 1,
ovarian cancer) had stable disease. Data indicated that
the combination therapy was well tolerated with no in-
crease in toxicities over those expected for the individual
agents and no unexpected drug-drug interactions. Fur-
ther, the pharmacokinetic profile of the combination
therapy was similar to the profile of each drug as a single
agent. Based on these results, a randomized phase II trial
was initiated to evaluate the potential of indoximod in
combination with docetaxel in patients with metastatic
breast cancer (NCT01792050). Two more phase Ib/II
trials of combined indoximod and chemotherapy are
being conducted; indoximod plus albumin-bound pac-
litaxel (nab-paclitaxel) and gemcitabine in pancreatic
cancer (NCT0277881) and indoximod plus temozolo-
mide in brain tumors (NCT02052648).
Indoximod is also being tested in combination with
other immunotherapy, such as a cancer vaccine or im-
mune checkpoint inhibitor. First, a phase Ib study of com-
bined indoximod and DC cancer vaccine (AD.p53DC)
was presented at the ASCO annual meeting in 2013 [87].
The combination was well tolerated with no dose-limiting
toxicities. The safety profile was consistent with the
known monotherapy safety profiles for each agent. Among
32 patients enrolled in the phase I study, treatment dis-
continuations were all due to disease progression, not due
to toxicities. No objective responses to the study therapy
were noted, but after subsequent post-vaccine chemother-
apy, 6 of 10 breast cancer patients treated with carbopla-
tin/gemcitabine or gemcitabine alone showed response.
This finding supports the hypothesis that immunotherapy
treatments may sensitize patients to subsequent lines of
therapy. Currently, a phase II trial is looking at the re-
sponse to indoximod plus AD.p53DC vaccine followed by
salvage carboplatin/gemcitabine in previously treated
breast cancer patients (NCT01042535).
A second combination of indoximod with immuno-
therapy–a randomized, double-blind, phase II study of
indoximod or placebo following infusion of sipuleucel-
T–is being conducted in men with asymptomatic or
minimally symptomatic metastatic castration-resistant
prostate cancer (NCT01560923). Finally, another phase
Ib/II study of combined indoximod and ipilimumab is
recruiting patients with melanoma (NCT02073123).
Data from a phase I trial of an IDO peptide vaccine in
15 HLA-A2-positive patients with stage III-IV NSCLC
were recently published [78]. The vaccine was well toler-
ated, with no severe toxicity. One patient developed a
partial response, and 6 patients (40 %) demonstrated
stable disease for ≥ 8.5 months [78]. Meanwhile, a phase
Ib study of combined IDO peptide vaccine and temozo-
lomide is under way (NCT01543464).
NLG919 is the most recently developed orally bio-
available IDO1 inhibitor [79]. It was developed by the
same company that developed the IDO pathway in-
hibitor indoximod. In preclinical setting, NLG919 was
found to be as effective as indoximod in enhancing
the survival in mice with glioblastoma and was syner-
gistic when combined with standard chemo-radiation
therapy [75]. Based on this preclinical finding, a phase
I dose-escalating study is recruiting patients with ad-
vanced solid tumors (NCT02048709).
Future directions
Blockade of immune-inhibitory pathways, e.g., through
inhibition of the IDO pathway, is emerging as an im-
portant modality for the treatment of cancer. However,
single-agent treatments have partial anti-tumor activity
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in preclinical models and in cancer patients, as de-
scribed above. The tumor microenvironment shows evi-
dence of multiple immune-inhibitory mechanisms present
concurrently such as PD-1/programmed cell death-ligand
1 (PD-L1) or cytotoxic T-lymphocyte-associated protein 4
(CTLA4) signaling as well as IDO signaling (Fig. 2) [82].
Remarkable clinical activity with rapid and deep
tumor reduction has been reported in 65 % of 53 pa-
tients with advanced melanoma treated with a com-
bination of nivolumab, which is different from the
published data on monotherapy PD-1 inhibitor, and
ipilimumab, CTLA4 inhibitor [88]. We suggest that
combination immunotherapies such as IDO inhibitors
with other immune checkpoint inhibitors or cancer
vaccines may be required for optimal therapeutic ef-
fect. In fact, combining IDO inhibitors with anti PD-
1/PD-L1 and anti-CTLA has increased the number of
intratumoral CD8+ T cells, resulting in restored inter-
leukin (IL)2 production [82, 89]. From the standpoint
of immunology, immunotherapy is considered a ‘double-
edged sword’ in that it can trigger two opposite immuno-
logic processes. For example, among cytokines, which are
major immune players, IL6 and IL10 are known to cause
immune suppression or tolerance, leading to tumor pro-
gression, whereas IL2, IL12, IL23, interferon (INF)-alpha
and INF-gamma are crucial in immune activation, leading
to tumor suppression [90]. We may be able to better
modulate the immune system by targeting both aspects:
combining IDO inhibitors to block immune tolerance
with immune activators such as IL2 or vaccines.
IDO inhibitors might work as single agents if IDO ex-
pression in the tumor microenvironment is the rate-
limiting step and there are no other barriers to antitumor
immune response, such as inadequate priming of the im-
mune system, i.e., a lack of CD8+ T cells at the tumor site.
Therefore, selection of biomarkers suggesting more bene-
fit with IDO inhibitors, including expression of IDO and
CD8+ T cells at the tumor site, should be investigated.
Another strategy to induce tumor sites to be more
inflamed, or more primed for tumor immunity, is to ad-
minister targeted therapies, such as tyrosine kinase in-
hibitors. Frederick et al. reported that melanoma antigen
expression and CD8+ T cells at the tumor sites were en-
hanced at the time of progression in patients with ad-
vanced melanoma treated with a BRAF inhibitor [91].
Interestingly, PD-L1 expression was also increased with
BRAF inhibitor therapy, providing support for potential
synergy of BRAF-targeted therapy and an immune
checkpoint inhibitor. Further, as mentioned before, in-
hibition of IDO was demonstrated to contribute to the
antitumor effects of imatinib in a preclinical model of
gastrointestinal stromal tumor by suppressing Tregs and
Fig. 2 Potential mechanism of combinatory synergism between three methods of immune checkpoint blockade. PD-1 or CTLA4 signaling inhibits
proliferation of effector T cells. In addition, some studies have suggested that Tregs are also partly activated by PD-1 or CTLA4 signaling [100]. IDO
signaling induces tumor immune tolerance by both suppressing effector T cells and activating Tregs. Therefore, if PD-1 or CTLA-4 signaling blockade is
combined with an IDO inhibitor, effector T cells may be further activated and Tregs may be further suppressed. The result could be more effective
reversal of immune tolerance and enhanced anti-tumor immune response. APC, antigen-presenting cell; PD-1, programmed cell death-1; PD-L1,
programmed cell death-ligand 1; CTLA4, cytotoxic T-lymphocyte-associated protein 4; B7-1/2, peripheral membrane proteins found on activated APCs
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augmenting CD8+ T cells, which were partially induced
by imatinib therapy [68]. A strategy of combining IDO
inhibitors and various targeted therapies is strongly sug-
gested for potential synergy.
As described above, in the phase I dose-escalating trials,
IDO inhibitor monotherapy was generally very well toler-
ated. In addition to the excellent safety profile of IDO
monotherapy, preclinical data that IDO inhibition helps
overcome chemoresistance have prompted investigators to
study combinations of an IDO inhibitor with other che-
motherapeutic agents. As noted above, the combination of
indoximod and docetaxel had a promising response rate
in a preliminary report of the phase I trial [86].
Conclusion
Preclinical and preliminary clinical data demonstrates evi-
dence to anti-tumor activity of IDO inhibitors. However,
IDO inhibitors in combination with immunotherapies,
targeted agents, and chemotherapy merit thorough inves-
tigation in cancer, and more clinical trials with immune
monitoring are warranted.
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